Muro K, Uetake H, Tsuchihara K, Shitara K, et al. PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus
panitumumab or bevacizumab as first-line treatment in patients with RAS
(KRAS/NRAS) wild-type metastatic colorectal cancer. Ann Oncol 2019;30 Suppl 4:iv10.
PMID: 32084926